NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$31.12
-0.32 (-1.02%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
24d
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NAMS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NAMS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $31.12, which is considered oversold relative to its 30-day fair value range of $32.10 to $35.34.
Technical Outlook: Technically, NAMS is in a uptrend. Immediate support is located at $30.17, while resistance sits at $34.95.
Market Sentiment: NAMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.63 (+57.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NAMS is in a uptrend. Immediate support is located at $30.17, while resistance sits at $34.95.
Market Sentiment: NAMS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $49.63 (+57.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$32.10 -
$35.34
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding NAMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.9% below Wall St target ($49.63)
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$32.10 -
$35.34
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$3.20
(10.3%)
Support & Resistance Levels
Support Level
$30.17
Resistance Level
$34.95
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-21.00
Wall Street Target
$49.63
(+57.9%)
Revenue Growth (YoY)
-98.8%
Last updated: January 30, 2026 9:44 PM ET
Data refreshes hourly during market hours. Next update: 10:44 PM
Data refreshes hourly during market hours. Next update: 10:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
3
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
James N Topper
BUY
660 shares
2025-09-15
Louise Frederika Kooij
SELL
150000 shares
2025-09-09
James N Topper
BUY
1260 shares
2025-09-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.
